Literature DB >> 3758052

Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.

L J Piddock, J M Diver, R Wise.   

Abstract

One hundred urine isolates Enterobacteriaceae screened for resistance to 30 micrograms nalidixic acid by disc diffusion test were examined by MIC determination for in vitro susceptibility to nalidixic acid, ciprofloxacin, enoxacin, gentamicin, nitrofurantoin, trimethoprim, cephalexin and ceftazidime. Those resistant to nalidixic acid and also gentamicin or a cephalosporin were further examined to determine the mechanism of resistance. Compared to the total urine isolates of Enterobacteriaceae from the same time period, this population as a whole was less susceptible to all antimicrobials tested except gentamicin. Strains that exhibited multiple resistance had the conventional mechanisms of resistance to those antimicrobials. No multiply resistant strains had a permeability barrier due to outer membrane protein alterations causing cross-resistance to chemically unrelated classes of antimicrobials.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758052     DOI: 10.1007/bf02075696

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  22 in total

1.  Model for regulation of Escherichia coli DNA repair functions.

Authors:  L J Gudas; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1975-06       Impact factor: 11.205

2.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

3.  Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors:  M W Hane; T H Wood
Journal:  J Bacteriol       Date:  1969-07       Impact factor: 3.490

4.  Mutation affecting resistance of Escherichia coli K12 to nalidixic acid.

Authors:  J Hrebenda; H Heleszko; K Brzostek; J Bielecki
Journal:  J Gen Microbiol       Date:  1985-09

5.  In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.

Authors:  R Wise; J M Andrews; G Danks
Journal:  J Antimicrob Chemother       Date:  1984-03       Impact factor: 5.790

6.  Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes.

Authors:  C C Sanders; W E Sanders; R V Goering; V Werner
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

7.  A simple method for the identification of aminoglycoside-modifying enzymes.

Authors:  J A van de Klundert; J S Vliegenthart; E van Doorn; G P Bongaerts; L Molendijk; R P Mouton
Journal:  J Antimicrob Chemother       Date:  1984-10       Impact factor: 5.790

8.  METHOD FOR THE DETECTION OF SIGNIFICANT BACTERIURIA IN LARGE GROUPS OF PATIENTS.

Authors:  D A LEIGH; J D WILLIAMS
Journal:  J Clin Pathol       Date:  1964-09       Impact factor: 3.411

9.  In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.

Authors:  S A Chartrand; R K Scribner; A H Weber; D F Welch; M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

View more
  6 in total

Review 1.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

2.  Resistance to quinolones.

Authors:  R P Mouton
Journal:  Pharm Weekbl Sci       Date:  1987-12-11

3.  In-vitro activity of lomefloxacin (SC-47111) and other quinolones.

Authors:  Z M Sun; J P Maskell; S C Sehgal; J D Williams
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

Review 4.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

5.  Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.

Authors:  J Fung-Tomc; B Kolek; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 6.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.